Mason Carrico
Stock Analyst at Stephens & Co.
(3.43)
# 895
Out of 5,179 analysts
77
Total ratings
44.12%
Success rate
6.1%
Average return
Main Sectors:
Stocks Rated by Mason Carrico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NTRA Natera | Maintains: Overweight | $197 → $235 | $182.65 | +28.66% | 6 | Nov 13, 2025 | |
| PACB Pacific Biosciences of California | Maintains: Overweight | $1.8 → $2 | $1.26 | +58.73% | 6 | Nov 10, 2025 | |
| HOLX Hologic | Downgrades: Equal-Weight | $78 → $76 | $75.67 | +0.44% | 6 | Oct 22, 2025 | |
| NEO NeoGenomics | Maintains: Overweight | $6.5 → $11 | $7.19 | +52.99% | 2 | Sep 2, 2025 | |
| VCEL Vericel | Reiterates: Overweight | $67 | $29.34 | +128.36% | 3 | Jun 16, 2025 | |
| ILMN Illumina | Reiterates: Overweight | $105 | $117.67 | -10.77% | 8 | May 20, 2025 | |
| TXG 10x Genomics | Reiterates: Overweight | $14 | $19.48 | -28.13% | 6 | May 15, 2025 | |
| CDNA CareDx | Reiterates: Overweight | $40 | $16.78 | +138.38% | 10 | May 5, 2025 | |
| GKOS Glaukos | Maintains: Overweight | $140 → $115 | $103.18 | +11.46% | 1 | May 2, 2025 | |
| VCYT Veracyte | Reiterates: Overweight | $45 | $30.01 | +49.95% | 7 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $55 | $84.61 | -35.00% | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $4.32 | +38.89% | 2 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $17 | $17.89 | -4.97% | 2 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $52 | $55.31 | -5.98% | 2 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $20 | $4.28 | +367.29% | 4 | Jan 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $41 | $23.53 | +74.25% | 7 | Jan 2, 2025 |
Natera
Nov 13, 2025
Maintains: Overweight
Price Target: $197 → $235
Current: $182.65
Upside: +28.66%
Pacific Biosciences of California
Nov 10, 2025
Maintains: Overweight
Price Target: $1.8 → $2
Current: $1.26
Upside: +58.73%
Hologic
Oct 22, 2025
Downgrades: Equal-Weight
Price Target: $78 → $76
Current: $75.67
Upside: +0.44%
NeoGenomics
Sep 2, 2025
Maintains: Overweight
Price Target: $6.5 → $11
Current: $7.19
Upside: +52.99%
Vericel
Jun 16, 2025
Reiterates: Overweight
Price Target: $67
Current: $29.34
Upside: +128.36%
Illumina
May 20, 2025
Reiterates: Overweight
Price Target: $105
Current: $117.67
Upside: -10.77%
10x Genomics
May 15, 2025
Reiterates: Overweight
Price Target: $14
Current: $19.48
Upside: -28.13%
CareDx
May 5, 2025
Reiterates: Overweight
Price Target: $40
Current: $16.78
Upside: +138.38%
Glaukos
May 2, 2025
Maintains: Overweight
Price Target: $140 → $115
Current: $103.18
Upside: +11.46%
Veracyte
Mar 26, 2025
Reiterates: Overweight
Price Target: $45
Current: $30.01
Upside: +49.95%
Mar 26, 2025
Reiterates: Overweight
Price Target: $55
Current: $84.61
Upside: -35.00%
Mar 19, 2025
Reiterates: Overweight
Price Target: $6
Current: $4.32
Upside: +38.89%
Mar 18, 2025
Reiterates: Equal-Weight
Price Target: $17
Current: $17.89
Upside: -4.97%
Mar 6, 2025
Reiterates: Overweight
Price Target: $52
Current: $55.31
Upside: -5.98%
Jan 16, 2025
Reiterates: Equal-Weight
Price Target: $20
Current: $4.28
Upside: +367.29%
Jan 2, 2025
Reiterates: Overweight
Price Target: $41
Current: $23.53
Upside: +74.25%